1. Study involved 104 patients with Crohn's disease of the pouch.
2. Comparisons were made between ustekinumab and vedolizumab.
3. Ustekinumab yielded 62% clinical response at 3 months.
4. Higher treatment durability was noted for ustekinumab.
5. Endoscopic response at 1 year: 41% for ustekinumab.
6. Adverse effects for both treatments were mild and infrequent.
7. Study suggests earlier use of ustekinumab in treatment protocols.

Source: Inflammatory Bowel Diseases